Translator: 文𤦍（manpui)#3013 by Canada Vancouver Sailing Farm
Injecting an experimental CCP virus vaccine does not prevent infection! The seven German tourists to South Africa mentioned in the article published by THE LANCET on the 18th of this month were all infected with the omicron variant of the CCP virus within 22 to 59 days after the injection of 3 doses of the COVID-19 virus vaccine is a good example.
This text is excerpted from the case in the article published by medical professionals from Division of Medical Virology, Faculty of Medicine and Health Sciences, University of Stellenbosch, Cape Town, South Africa, the National Health Service Laboratory Service, Tygerberg Campus, Cape Town, South Africa, Institute of Infectious Disease and Molecular Medicine, University of Western Cape, Cape Town, South Africa, Department of Bioscience, University of Western Cape, Cape Town , South Africa and Constanze Kuhlmann of University Hospital, LMU Munich, Munich , Germany on January 18, 2022 in THE LANCET titled: “Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose”
Seven German tourists who received 3 doses of the CCP virus vaccine were infected with the omicron variant of the CCP virus (PANGO lineage B.1.1.529, Nextstrain clade 21K) between November 30 and December 2, 2021.
The seven were members of two unrelated social groups in Germany, including five white women and two white men, aged 25-39. Because they are all engaged in medical-related occupations, they all received 3 shots of the CCP virus vaccine. There was no history of SARS-CoV-2 virus infection before infection with omicron virus.
Among them, the three vaccine injections of 3 women and 2 men were all BioNTech’s BNT162b2 vaccine, a 27-year-old woman was injected with BioNTech’s BNT162b2 vaccine in the first 2 injections, the third injection was Moderna’s CX-024414 vaccine, and the last one, the 27-year-old woman received the first dose of AstraZeneca’s ChAdOx1-S vaccine, followed by a dose of BNT162b2 and a booster dose of the same vaccine.
After the booster shot, all seven had similar levels of viral spike protein binding antibodies as four weeks after the second dose.
Chest pressure, Dry cough, Fatigue, Headache, Rhinitis, Sinus pressure and Sore throat after infection with the omicron variant of the CCP virus are the most common symptoms. In particular, sore throat, fatigue, headache, and dry cough are very common, and dry cough and fatigue are almost always present.
Of these 7, 4 had mild COVID-19 symptoms, 3 had moderate (shortness of breath) COVID-19 symptoms, and blood oxygenation levels (SPO2) >94%, belonging to within normal limits. No one was hospitalized or died.
The log10 value of viral RNA load per milliliter of RNA swab eluate was 4.07-8.22, with an average value of 5.83. Anti-spike antibody levels in serum ranged from 15,000 to 40,000 AU/mL, with an average of 22,000 AU/mL.
All received the 3rd dose (booster shot) 21–37 weeks after the second shot and were infected 22 to 59 days after the booster shot.
The conclusion is experimental CCP virus vaccines do not prevent CCP virus!
Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose
Correspondence：Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose
Supplementary Material：Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose